Peptide ligand engineering, formulation control, and functional optimization for cell- and tissue-directed lipid nanoparticle systems.
Peptide functionalized lipid nanoparticles have become an important strategy in advanced nucleic acid and biomacromolecule delivery because peptides can support receptor recognition, cellular internalization, membrane interaction, and intracellular trafficking beyond what conventional non-functionalized LNPs typically achieve. However, effective peptide-functionalized systems require more than surface decoration. Their success depends on coordinated control of ionizable lipid composition, helper lipid balance, PEG-lipid behavior, peptide conjugation strategy, ligand density, linker design, colloidal stability, payload compatibility, and downstream functional validation. BOC Sciences provides peptide functionalized lipid nanoparticle development services designed to help researchers build, refine, and evaluate peptide-engineered LNP platforms for mRNA, siRNA, pDNA, oligonucleotides, proteins, peptides, and selected small molecules. Our workflow integrates LNP formulation, peptide installation, physicochemical characterization, and performance-oriented screening to support efficient progression from concept to optimized candidate.
Structure of Peptide Functionalized LNPWe offer a modular service framework for peptide functionalized lipid nanoparticle development, covering carrier architecture design, peptide conjugation strategy selection, formulation refinement, and application-specific screening. Our services are tailored for pharmaceutical and biotechnology teams seeking stronger cell uptake, improved tissue selectivity, better intracellular delivery performance, and clearer structure-function understanding in peptide-engineered LNP systems.
We define a rational development space based on the target tissue, cell population, payload type, biological barrier, and intended peptide function so that formulation variables align with the actual delivery objective.
We establish a robust non-functionalized or peptide-ready LNP backbone before or alongside ligand installation to ensure strong encapsulation, stability, and delivery competence after surface modification.
We support peptide functionalization strategies using peptide formats selected for receptor accessibility, membrane interaction, conjugation feasibility, and compatibility with LNP colloidal behavior.
Peptide-enabled delivery claims require comparative evidence. We design screening workflows that distinguish meaningful peptide-mediated enhancement from nonspecific uptake or adsorption effects.
We characterize the particle properties most likely to change during peptide functionalization and most likely to affect biological behavior during downstream studies.
We use stepwise optimization to improve selectivity and potency while maintaining robust formulation behavior and practical reproducibility.
Effective peptide functionalized lipid nanoparticle design requires control over both the delivery core and the peptide presentation layer. We combine formulation expertise with application-specific engineering logic to improve the probability of selective and productive delivery.
Advance beyond generic ligand decoration with a development workflow focused on peptide functionality, formulation integrity, and more reliable delivery behavior.
Our peptide functionalized LNP development services are suitable for diverse payload classes and research objectives. We adapt formulation architecture and peptide surface engineering strategies to the intended delivery context rather than applying a one-size-fits-all workflow.
| Development Category | Peptide Functionalized LNP Scope |
|---|---|
| Peptide-Functionalized LNPs for mRNA Delivery | Development of peptide-modified mRNA-loaded systems for receptor-aware uptake studies, intracellular expression optimization, and tissue-directed delivery exploration. |
| Peptide-Functionalized LNPs for siRNA Delivery | Formulation and screening of peptide-enabled siRNA LNPs with emphasis on selective internalization, intracellular release, and gene-silencing-oriented delivery design. |
| Gene Delivery-Oriented Peptide LNP Development | Engineering of peptide-functionalized LNP systems for plasmid, editing-related, or other nucleic acid cargoes requiring cell-specific access and productive intracellular trafficking. |
| Encapsulation-Focused Development | Optimization of loading efficiency and formulation integrity for peptide-modified systems where ligand engineering may alter assembly or payload retention. |
| Characterization of Peptide-Modified LNP Attributes | Assessment of size, PDI, zeta potential, morphology, peptide-related surface effects, and other physicochemical parameters critical to delivery performance. |
| Peptide-Functionalized LNP Stability Evaluation | Investigation of storage and dispersion stability after peptide incorporation, with attention to aggregation, fusion, and payload leakage risk. |
| Scale-Conscious LNP Process Development | Refinement of peptide-functionalized LNP preparation workflows for reproducibility, process continuity, and smoother transition to broader production-oriented studies. |
| Lipid Nanoparticles for Drug Delivery | Broader support for teams integrating peptide engineering into advanced lipid nanoparticle drug delivery strategies across multiple payload modalities. |
Our peptide functionalized LNP development services are designed to support multiple delivery strategies by combining formulation optimization, peptide engineering, and application-specific screening logic.
✔ Receptor-Targeting Peptides
We support peptide-functionalized LNP systems for receptor-mediated delivery studies where peptide ligands are used to improve selective association with target cell populations and tissue-relevant models.
✔ Cell-Penetrating Peptides
Our services can support LNP development programs that use cell-penetrating peptides to improve cellular access when uptake is a limiting factor in delivery performance.
✔ Endosomal Escape-Associated Peptides
We optimize peptide-LNP systems for projects exploring whether membrane-interactive or fusogenic peptide motifs can improve productive intracellular release after particle internalization.
✔ Tumor-Directed Peptide LNP Delivery
We develop peptide-modified LNP systems for cancer-focused delivery studies by integrating receptor-aware peptide selection, payload-compatible formulation design, and comparative screening in tumor-relevant models.
✔ Immune Cell-Oriented Peptide LNPs
We support peptide-functionalized LNP development for immunology-oriented research involving macrophages, dendritic cells, lymphoid tissue-associated cells, and other immune-relevant targets.
✔ Multifunctional Peptide Display Concepts
We also support multifunctional LNP designs in which peptides contribute to targeting, internalization, and trafficking-related performance within one coordinated delivery strategy.
We assess payload type, target cell or tissue, peptide role, formulation constraints, and intended study objectives to define a practical peptide-functionalized LNP development plan.
We develop the LNP core system and integrate selected peptide elements through suitable insertion or conjugation strategies while maintaining particle quality.
Peptide-functionalized and control formulations are characterized and evaluated through physicochemical and functional studies to identify specificity, uptake, stability, and delivery performance trends.
Based on screening outcomes, we refine composition and peptide presentation variables and provide a structured report to support informed advancement of lead peptide-functionalized LNP candidates.
Challenge: A client's mRNA-LNP formulation for neurodegenerative disease showed excellent in vitro potency but failed to demonstrate therapeutic protein expression in the brain during in vivo systemic administration due to restriction by the BBB.
Diagnosis: Standard LNPs lack the active transport mechanism required to bypass the tight junctions of brain endothelial cells. Biodistribution studies confirmed that over 80% of the dose was sequestered in the liver, with negligible CNS penetration.
Solution: Our team designed a customized Angiopep-2-functionalized LNP to leverage receptor-mediated transcytosis. We synthesized a proprietary DSPE-PEG-maleimide linker to covalently graft thiol-terminated Angiopep-2 peptides. By employing a post-insertion technique, we precisely controlled peptide density on the preformed LNP surface to avoid particle destabilization. The optimal ligand density was determined by surface plasmon resonance (SPR) to ensure high affinity (KD < 10 nM) for the LRP1 receptor while maintaining the structural integrity of the mRNA cargo.
Result: The peptide-modified LNPs achieved a 6.5-fold increase in brain accumulation and successfully triggered widespread mRNA translation across the cerebral cortex and hippocampus.
Challenge: A research group faced significant off-target toxicity when delivering a cytotoxic payload via LNPs, as the particles were rapidly cleared by the mononuclear phagocyte system (MPS) before reaching the target solid tumor.
Diagnosis: The formulation relied solely on the passive enhanced permeability and retention (EPR) effect, which was insufficient for this specific hypovascular tumor model. High accumulation in the spleen and liver led to systemic side effects that limited the maximum tolerated dose.
Solution: We implemented a cRGD-peptide targeting strategy targeting the αvβ3 integrins overexpressed on tumor neovasculature. Our synthesis team developed a one-pot microfluidic assembly process in which the cRGD-lipid conjugate was integrated during the initial mixing phase to ensure homogeneous distribution. We utilized a branched PEG spacer (4-arm PEG) to increase peptide valency, significantly enhancing LNP avidity toward malignant cells. The final product was validated using a fluorescence-based binding assay to confirm the accessibility of the peptide motifs on the LNP exterior.
Result: The tumor-to-liver uptake ratio improved by 320%, allowing for a 50% dose reduction while achieving superior tumor growth inhibition.
Integrated Design LogicWe approach peptide-functionalized LNP development as a combined formulation and biointerface engineering problem, not merely a surface conjugation task.
Peptide Engineering FlexibilityOur workflows support targeting peptides, penetrating peptides, trafficking-related motifs, and multifunctional design concepts across diverse project needs.
Payload VersatilityOur workflows support multiple cargo classes and can be adapted to discovery-stage and optimization-stage peptide-functionalized LNP programs.
Characterization-Oriented DevelopmentPeptide-modified formulations are supported by structured physicochemical analysis to reveal how surface engineering affects overall LNP quality.
Optimization for Real Research QuestionsWe focus on practical issues researchers face, including peptide masking, formulation instability, insufficient uptake specificity, and inconsistent performance across models.
No. If peptide density is too low, receptor engagement may be insufficient to create a clear targeting advantage. However, if the density is too high, it may introduce steric crowding, alter surface properties, reshape protein adsorption behavior, or increase nonspecific uptake, which can reduce the actual targeting effect. In practice, successful development usually depends on identifying an optimal density window rather than maximizing the number of ligands on the surface. At BOC Sciences, we can support integrated studies covering conjugation strategy, formulation screening, and physicochemical characterization, helping clients determine a more effective ligand density range based on real formulation performance.
Selecting a peptide should not be based only on whether it binds a receptor. A sound selection strategy should also consider target expression level, receptor internalization behavior, serum exposure conditions, compatibility with the PEG or lipid shell, and whether conjugation may alter particle size, surface charge, or colloidal stability. In many projects, failure does not come from poor peptide affinity alone, but from insufficient surface exposure, an unsuitable linker, or excessive steric hindrance after formulation. For drug developers, a more practical path is to screen several candidate peptides first, then optimize ligand density and formulation architecture using cellular uptake and functional readouts.
The core value of peptide-functionalized lipid nanoparticles is not simply the addition of a surface ligand. Their real advantage lies in reshaping receptor recognition, membrane interaction, and cellular uptake pathways to improve tissue selectivity, intracellular delivery efficiency, and, in some cases, post-endocytic transport performance. For drug development teams, this makes peptide-functionalized LNPs especially attractive when conventional LNPs are not sufficient for extrahepatic delivery, brain targeting, pulmonary delivery, or biological barrier penetration. As a result, they have become a highly relevant platform in the development of RNA therapeutics, peptide cargoes, and selected small-molecule delivery systems.
The most common challenges usually fall into four areas. First, peptide conjugation may reduce nanoparticle stability and cause aggregation or particle size drift. Second, protein adsorption in biological media may mask the peptide and weaken its intended targeting effect. Third, cellular uptake may increase without delivering a corresponding gain in intracellular release or biological function. Fourth, the conjugation process may be difficult to reproduce consistently across batches. For drug development teams, this means the key question is no longer whether a peptide can be attached to the LNP surface, but whether that modification produces a measurable and reproducible improvement in delivery performance under relevant experimental conditions.
Performance should never be judged by a single parameter. A meaningful evaluation should answer several questions at once: whether the particles remain stable, whether the payload is preserved, whether uptake in target cells increases, whether off-target uptake stays controlled, whether the downstream functional response improves, and whether the mechanism is consistent with the intended receptor pathway. A practical framework is to combine physicochemical characterization, binding and uptake studies, intracellular trafficking assessment, and functional output analysis. At BOC Sciences, we can design studies around these decision points to help clients identify which peptide-functionalized LNP candidates are truly worth advancing.
